EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma

John Wen-Cheng Chang, Chien-Jung Huang, Wen-Kuan Huang, Yu-Chao Wang, Jia-Juan Hsieh, Yao-Yu Chang, Yen-Lin Huang, Chia-Ling Wu, Yeh-Han Wang, Shu-Jen Chen, Kien Thiam Tan, Chiao-Ping Chen iD und 1 weitere

Clinical & Translational Immunology · 2023-01 · 12 (8)

DOI: 10.1002/cti2.1465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 29.08.2023. Verfasst von John Wen-Cheng Chang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Tai…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Genomic biomarkers predicting immune checkpoint inhibitor (ICI) treatment outcomes for Asian metastatic melanoma have been rarely reported. This study presents data on next‐generation sequencing (NGS) and tumour microenvironment biomarkers in 33 cases.

Methods

Thirty‐three patients with advanced melanoma, who underwent ICI treatment at the Chang Gung Memorial Hospital in Taiwan, were recruited. The study evaluated clinical outcomes, including response rate, disease control rate, progression‐free survival (PFS) rate and overall survival (OS) rate. Archived tissue samples from 33 cases were subjected to NGS by ACTOnco, and ACTTME was employed in 25 cases.

Results

The most prevalent driver mutations were BRAF mutations (24.2%), followed by NRAS (15.2%), KIT (12.1%), KRAS (9.1%) and NF1 (9.1%) mutations. Acral/mucosal melanomas exhibited distinct mutation patterns compared to non‐acral melanomas. Tumour mutational burden estimated using ACTOnco was not associated with ICI efficacy. Notably, genetic alterations in the p53 pathway ( CDKNA2 loss, MDM2 gain/amplification and TP53 mutation) accounted for 36.4% and were significantly associated with unfavourable PFS (median PFS 2.7 months vs. 3.9 months, P = 0.0394). Moreover, 26 genes were identified as differentially expressed genes that were upregulated in patients with clinical benefits compared to those without benefits. Four genes, GZMH , GZMK , AIM2 and CTLA4 , were found to be associated with both PFS and OS.

Conclusion

Genetic alterations in the p53 pathway may be critical in Asian patients with melanoma undergoing ICI treatment. Further investigation is required to explore this mechanism and validate these findings.

Schlagwörter

Stichwörter der Autor:innen

ICIsgenomic and TME biomarkersmelanomap53

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.
  • Institute of Biomedical Informatics National Yang Ming Chiao Tung University Taipei Taiwan.
  • Department of Dermatology, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.
  • School of Medicine National Tsing-Hua University Hsinchu Taiwan.
  • Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou Institute of Stem Cell and Translational Cancer Research Taoyuan Taiwan.
  • ACT Genomics Co., Ltd Taipei Taiwan.

ORCID-Profile: Chiao-Ping Chen, Chiao-En Wu

Förderung

  • National Science and Technology Council

Zitieren

APA

Chang, J. W., Huang, C. J., Huang, W. K., Wang, Y. C., Hsieh, J. J., Chang, Y. Y., Huang, Y. L., Wu, C. L., Wang, Y. H., Chen, S. J., Tan, K. T., Chen, C. P., & Wu, C. E. (2023). Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. Clinical & Translational Immunology, 12(8). https://doi.org/10.1002/cti2.1465

Vancouver

Chang JW, Huang CJ, Huang WK, Wang YC, Hsieh JJ, Chang YY, et al. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. Clinical & Translational Immunology. 2023;12(8). doi:10.1002/cti2.1465

BibTeX
@article{Chang2023,
  author = {Chang, John Wen-Cheng and Huang, Chien-Jung and Huang, Wen-Kuan and Wang, Yu-Chao and Hsieh, Jia-Juan and Chang, Yao-Yu and Huang, Yen-Lin and Wu, Chia-Ling and Wang, Yeh-Han and Chen, Shu-Jen and Tan, Kien Thiam and Chen, Chiao-Ping and Wu, Chiao-En},
  title = {Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma},
  journal = {Clinical & Translational Immunology},
  year = {2023},
  volume = {12},
  number = {8},
  doi = {10.1002/cti2.1465}
}
Kostenlos starten →